Loading
Loading
Research Overview
Peptide incorporating the p53 HDM2-binding domain fused to a transmembrane-penetrating sequence; proposed to insert into the membranes of cancer cells (which overexpress HDM2) and induce selective membranolysis, while leaving normal cells unaffected.
PNC-27 combines a 14-amino acid sequence from p53's MDM2-binding domain with a membrane-penetrating sequence to create a chimeric peptide studied in preclinical cancer cell biology research. The rationale for its development draws on the p53 tumour suppressor pathway, in which MDM2 normally promotes p53 degradation and is overexpressed in many cancer cell types. Preclinical studies have examined PNC-27's preferential activity in cancer cell models versus normal cell models in cell culture systems.
Sold strictly as a research chemical for non-human, in-vitro, and laboratory use
FDA approved compound
Prescription availability in Australia and internationally
In Australia, pnc-27 peptide has no TGA approval for therapeutic use. It is sold by Capital Peptides strictly as a research chemical for non-human, in-vitro, and laboratory research use only.
PNC-27 Peptide research is most relevant to protocols examining:
Cancer-selective membranolysis research targeting HDM2-overexpressing cells
p53–HDM2 interaction and tumour biology studies
Researchers exploring peptide-based oncology agents
Selective cancer cell apoptosis mechanism investigations
Initial phase
Compound begins accumulating in target tissue. Most researchers note subtle changes by end of week one. Baseline measurements recommended.
Early response
Downstream biological effects become detectable. Key biomarkers worth monitoring from this point.
Peak activity window
Effects compound in this window. Given limited human data, careful documentation is important.
Washout & review
Allow full washout (~5× half-life: ~Hours). Review data, confirm baseline recovery before any repeat protocol.
Peptide incorporating the p53 HDM2-binding domain fused to a transmembrane-penetrating sequence; proposed to insert into the membranes of cancer cells (which overexpress HDM2) and induce selective membranolysis, while leaving normal cells unaffected.
| Parameter | Value |
|---|---|
| Dose range | Under investigation |
| Schedule | Protocol-dependent |
| Route | Intravenous, Subcutaneous |
| Half-life | ~Hours |
experimental compound
strict research-use protocols required
Available from Capital Peptides
For research use only. Capital Peptides products are not approved by the TGA for therapeutic use. By purchasing you confirm you are a licensed research entity or qualified professional.